"Single-Domain Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An immunoglobulin fragment composed of one variable domain from an IMMUNOGLOBULIN HEAVY CHAIN or IMMUNOGLOBULIN LIGHT CHAIN.
Descriptor ID |
D061905
|
MeSH Number(s) |
D12.644.541.500.650.500.900 D12.776.124.486.485.680.650.500.900 D12.776.124.790.651.680.650.500.900 D12.776.377.715.548.680.650.500.897
|
Concept/Terms |
VHH Immunoglobulin Fragments- VHH Immunoglobulin Fragments
- Fragments, VHH Immunoglobulin
- Immunoglobulin Fragments, VHH
- Nanobodies
- VHH Fragments
- Fragments, VHH
VNAR Immunoglobulin Fragments- VNAR Immunoglobulin Fragments
- Fragments, VNAR Immunoglobulin
- Immunoglobulin Fragments, VNAR
- VNAR Fragments
- Fragments, VNAR
|
Below are MeSH descriptors whose meaning is more general than "Single-Domain Antibodies".
Below are MeSH descriptors whose meaning is more specific than "Single-Domain Antibodies".
This graph shows the total number of publications written about "Single-Domain Antibodies" by people in this website by year, and whether "Single-Domain Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 5 | 1 | 6 |
2018 | 3 | 2 | 5 |
2019 | 3 | 0 | 3 |
2020 | 9 | 1 | 10 |
2021 | 8 | 3 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Single-Domain Antibodies" by people in Profiles.
-
Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab. Br J Haematol. 2022 01; 196(1):e11-e14.
-
Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. EMBO J. 2021 10 01; 40(19):e107985.
-
Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. Nat Commun. 2021 08 03; 12(1):4676.
-
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. Elife. 2021 08 02; 10.
-
Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view. Biochim Biophys Acta Gen Subj. 2021 11; 1865(11):129974.
-
A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nat Commun. 2021 07 30; 12(1):4635.
-
Structural Basis for SARS-CoV-2 Nucleocapsid Protein Recognition by Single-Domain Antibodies. Front Immunol. 2021; 12:719037.
-
Engineered single-domain antibodies tackle COVID variants. Nature. 2021 07; 595(7866):176-178.
-
Rapid generation of potent antibodies by autonomous hypermutation in yeast. Nat Chem Biol. 2021 10; 17(10):1057-1064.
-
Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis. Cell Chem Biol. 2021 09 16; 28(9):1379-1388.e7.